Gilead Sciences Announces FDA Approval For Bixlenvo, The Smallest Once-Daily Single Tablet Regimen For The Treatment Of HIV In Adults Who Are Virologically Suppressed
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the
Read original at benzinga